Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.2639
-0.0120 (-4.35%)
At close: Dec 19, 2025, 4:00 PM EST
0.2515
-0.0124 (-4.70%)
After-hours: Dec 19, 2025, 7:57 PM EST
Co-Diagnostics Employees
Co-Diagnostics had 132 employees as of December 31, 2024. The number of employees decreased by 23 or -14.84% compared to the previous year.
Employees
132
Change (1Y)
-23
Growth (1Y)
-14.84%
Revenue / Employee
$3,848
Profits / Employee
-$243,799
Market Cap
16.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 132 | -23 | -14.84% |
| Dec 31, 2023 | 155 | 10 | 6.90% |
| Dec 31, 2022 | 145 | 44 | 43.56% |
| Dec 31, 2021 | 101 | 62 | 158.97% |
| Dec 31, 2020 | 39 | 14 | 56.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CODX News
- 3 days ago - Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India - PRNewsWire
- 4 days ago - Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation - PRNewsWire
- 12 days ago - Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025 - PRNewsWire
- 13 days ago - Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - PRNewsWire
- 4 weeks ago - Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health - PRNewsWire
- 4 weeks ago - Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA - PRNewsWire
- 5 weeks ago - Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Co-Diagnostics Reports Third Quarter 2025 Financial Results - PRNewsWire